Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRXBiotechnology
-$0.05 today
- Market cap
- $765.80M
- Beta
- 1.07
- P/E (TTM)
- -30.5
- EPS (TTM)
- -$0.07
Volume 2.02M
Average 2.48M
LXRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $12.76M fell 16.6% year over year, ahead of the -31.8% change in trailing-twelve-month research & development. Sequentially, it rose 13.9% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.
Context
- Research & development amounted to 122.7% of revenue in FY2025, down 149.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -16.6% holds above the trailing-twelve-month pace of -31.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 61.12M USD
- Year-over-year change
- -27.7%
- 4-year CAGR
- +2.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.12M | -27.7% |
| FY2024 | 2024-12-31 | 84.48M | +43.5% |
| FY2023 | 2023-12-31 | 58.89M | +11.5% |
| FY2022 | 2022-12-31 | 52.82M | -4.1% |
| FY2021 | 2021-12-31 | 55.05M | — |
Research & Development vs competitors
How LXRX compares with its peers on the latest reported figures
- LXRX's LTM Mar 2026 research & development of $58.28M is the 7th highest of the 11 companies compared; the peer median is $94.59M.
- Its year-over-year change of -31.8% is the lowest of 11, against a peer median of +10.1%.
- Research & development amounts to 83.7% of revenue for LXRX, versus a peer median of 32.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Jun 2026 | $197.76M | +15.5% | -13.1% | 21.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $72.56M | +54.7% | +49.8% | 20.1% | |
| LTM Mar 2026 | $58.28M | -31.8% | +5.0% | 83.7% | |
| LTM Sep 2026 | $50.35M | +37.5% | +19.1% | — | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| LTM Mar 2026 | $30.07M | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| Peer median (excluding LXRX) | $94.59M | +10.1% | +11.1% | 32.0% | |
Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 298K | 139K | 1.2M | 31.08M | 49.8M |
| Cost of Revenue | 55.05M | 52.52M | 58.97M | 616K | 274K |
| Gross Profit | (54.75M) | (52.38M) | (57.77M) | 30.47M | 49.53M |
| Gross Margin | -18371.8% | -37681.3% | -4798.0% | 98.0% | 99.4% |
| Research & Development | 55.05M | 52.82M | 58.89M | 84.48M | 61.12M |
| Selling, General & Admin | 0 | 0 | 0 | 131.9M | 37.32M |
| Operating Expenses | 32.34M | 48.38M | 113.98M | 227.58M | 98.44M |
| Depreciation & Amortization | 292K | 427K | 554K | 534K | 621K |
| EBITDA | (86.66M) | (100.03M) | (169.76M) | (184.29M) | (41.38M) |
| EBITDA Margin | -29081.9% | -71966.2% | -14099.3% | -592.9% | -83.1% |
| Operating Income | (87.09M) | (100.76M) | (171.75M) | (197.12M) | (48.91M) |
| Operating Margin | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% |
| Interest Income | 134K | 1.6M | 7.73M | 12.29M | 6.91M |
| Interest Expense | 802K | 2.78M | 13.1M | 15.58M | 8.34M |
| Other Income / Expenses | (668K) | (1.18M) | (5.37M) | (3.29M) | (1.43M) |
| Income Before Tax | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Pre-Tax Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (87.76M) | (101.94M) | (177.12M) | (200.4M) | (50.34M) |
| Net Margin | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% |
| EPS (Basic) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| EPS (Diluted) | (0.61) | (0.62) | (0.80) | (0.63) | (0.14) |
| Weighted Avg Shares | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
| Weighted Avg Shares (Diluted) | 145.65M | 165.73M | 221.13M | 320.03M | 363.05M |
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
Intrinsic Alpha fair value
Locked
Current Price
$1.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.